lifestyle.harcourthealth.com

Author: Boundless Bio, Inc.

Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting

April 17, 2026
Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026

March 17, 2026
Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

March 9, 2026
Boundless Bio to Participate in the Leerink Global Healthcare Conference

March 4, 2026
Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

February 10, 2026
Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway

January 20, 2026